©2008 The WJG Press and Baishideng.
World J Gastroenterol. Sep 28, 2008; 14(36): 5584-5589
Published online Sep 28, 2008. doi: 10.3748/wjg.14.5584
Published online Sep 28, 2008. doi: 10.3748/wjg.14.5584
Table 1 Clinical data of the study population
| UC | CD | |
| Number of subjects | 27 | 11 |
| Gender (female/male) | 15/12 | 3/8 |
| Age (yr, mean) | 42.5 (21-66) | 34.6 (21-70) |
| Disease duration (yr, mean) | 9.3 (0-38) | 5.6 (0-18) |
| Extent of disease: | ||
| Colon | 91 | 8 |
| Left side colitis | 14 | - |
| Proctitis | 4 | - |
| Ileocolitis | - | 1 |
| Prior surgery | 1 | 1 |
| Treatment at inclusion: | ||
| No treatment | 7 | 4 |
| 5-ASA (topical/systemic) | 19 | 4 |
| Azathioprine | 1 | 1 |
| Prednisone (topical/systemic) | 5 | - |
| Metronidazole | - | 1 |
- Citation: Wagner M, Peterson CG, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol 2008; 14(36): 5584-5589
- URL: https://www.wjgnet.com/1007-9327/full/v14/i36/5584.htm
- DOI: https://dx.doi.org/10.3748/wjg.14.5584